In vitro activity of ampicillin-sulbactam against clinical multiresistant Acinetobacter baumannii isolates

Journal of Chemotherapy

Volumn 8, Issue 6, 1996, Pages 416-419

  Gales, A C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

ampicillin sulbactam; Brazil; imipenem; in vitro activity; multiresistant Acinetobacter spp.; polymyxin B

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZTREONAM; CEFODIZIME; CEFOPERAZONE; CEFOTAXIME; CEFPIROME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; NETILMICIN; PEFLOXACIN; POLYMYXIN B; SULBACTAM; TIMENTIN;

ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; MULTIDRUG RESISTANCE; NONHUMAN;

EID: 0030475988     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1996.8.6.416     Document Type: Article

References (14)

1. Seifert H, Baginski R, Schulze A, Pulverer G. Antimicrobial susceptibility of Acinetobacter species. Antimicrob Agents Chemother 1993;37:750-753.
2. Traub WH, Spohr M. Antimicrobiol drug susceptibility of clinical isolates of Acinetobacter species (A. baumannii, A. haemolyticus, Genospecies 3 and Genospecies 6). Antimicrob Agents Chemother. 1989;33:1617-1619.
3. Smego RA Jr. Endemic nosocomial Acinetobacter calcoaceticus bacteremia. Arch Intern Med 1985;145:2174-2179.
4. Urban C, Go E, Mariano N, et al. Effect of sulbactam on infections caused by imipenem resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis 1993;167:448-451.
5. Tankovic J, Legrand P, Gatines G, Chemineau V, Brun-Bruisson, Duval J. Characterization of a hospital outbreak of imipenem-resistant Acinetobacter baumannii by phenotypic and genotypic typing methods. J Clin Microbiol 1994;32:2677-2681.
6. Horrevorts A, Bergaman K, Kollée L, Breuker I, Tjernberg I, Dijkshoorn L. Clinical and epidemiological investigations of Acinetobacter genomospecies 3 in a neonatal intensive care unit. J Clin Microbiol 1995;33:1567-1572.
7. Joly-Guillou ML, Bergogne-Bérézin E, Vieu JF. Épidémiologie et résistance aux antibiotiques des Acinetobacter en milieu hospitalier. Presse Méd 1990;19:357-361.
8. Go ES, Urban C, Burns J et al. Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 1994;344:1329-1332.
9. Sader HS, Pfaller MA, Mendes CF, Pignatari AC. Demonstration of inter-hospital spread of multiresistant Acinetobacter baumannii in São Paulo, Brazil by DNA macrorestriction analysis. The 35th Interscience Conference on Antimicrobial Agentes and Chemotherapy (ICAAC). San Francisco, CA, USA. September 17-20, 1995. Abstract J54.
10. National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial disk susceptibility tests. Approved Standard, M2-A5. Villanova, PA, 1993.
11. Horton J, Pankey GA. Polymyxin B, colistin and sodium colistimethate. Med Clin N Am 1982;66:135.
12. Suh B, Shapiro T, Jones R, Satishchandran V, Truant AL. In vitro activity of β-lactamase inhibitors against clinical isolates of Acinetobacter species. Diagn Microbiol Infect Dis 1995;21:111-114.
13. Bergogne-Bérézin E. The increasing significance of outbreaks of Acinetobacter spp. The need for control and new agents. J Hosp Infect 1995;30:441-452.
14. Wolfson JS, Hooper DC. Bacterial resistance to quinolones: mechanisms and clinical importance. Rev Infect Dis 1989;2 (suppl 5):960-968.